A. Sofinnova Investments, Inc. (“Sofinnova” or the “Firm”), is a registered investment adviser with the
U.S. Securities and Exchange Commission (“SEC”) pursuant to the Investment Advisers Act of 1940
(the “Adviser Act”). The Firm was established in 1976 and its principal office is located in Menlo Park,
California. It also has offices in; New York, New York; Montreal, Quebec; Boston, Massachusetts; and
Dorado, Puerto Rico. Sofinnova serves as an investment adviser to private pooled investment vehicles
(each, a “Fund”) and separately managed accounts (each, a “Separate Account” and collectively with
the “Funds,” the “Clients”)1. An affiliate of Sofinnova serves as the general partner (or similar
managing body) of each Fund.
Sofinnova is owned by Alain Azan, James Healy, Nathalie Auber, Maha Katabi, and Hooman Shahlavi.
The members of Sofinnova’s board of directors are James Healy, Nathalie Auber, Lars Ekman, and
Maha Katabi.
B. Sofinnova provides discretionary investment advisory services to the Clients. Sofinnova's advisory
services consist of (a) identifying and evaluating investment opportunities, (b) structuring, negotiating
and consummating investments on behalf of the Clients, (c) managing and monitoring such
investments, and (d) deciding when to exit such investments. As part of the management, Sofinnova
employees may serve on the board of directors of certain of the Clients’ portfolio investments. Certain
Clients primarily make private venture related investments (the "Venture Fund(s)"), while other
Clients primarily invest in publicly-traded equity securities (the "Public Clients"). Investments for all
Clients are generally made in the biotechnology and pharmaceuticals and related industries
(collectively, “Therapeutics”).
Sofinnova is affiliated with entities that serve as the general partners to each of the Funds (each, a
“General Partner”). Unless otherwise indicated, references in this brochure to “Sofinnova” or the
“Firm” include the General Partners. The following is a list of the General Partners:
General Partners:
Sofinnova Management VIII, L.L.C.
Sofinnova Management
IX, L.L.C.
Sofinnova Management X-A, L.L.C.
Sofinnova Management X, L.P.
Sofinnova Management XI, L.P.
Sofinnova Management XI, L.L.C.
Sofinnova Synergy Fund GP, L.L.C.
Sofinnova BioEquities GP LLC
C. Sofinnova provides investment advisory services to each Fund in accordance with the Fund’s offering
and governing documents (e.g., private placement memorandum and limited partnership agreement
(or analogous organizational document), as well as Sofinnova’s investment advisory agreement with
1 The persons and entities that invest in a Fund are generally referred to herein as “investors.” For the avoidance
of doubt, as used herein, the terms “Fund” and “Client” do not include “investors.”
the Fund and contractual side letters with such Fund’s investors and contractual side letters with such
Fund’s investors (collectively, the “Fund Documents”). The Firm provides investment advisory
services each Separate Account in accordance with its investment advisory agreement with the
Separate Account (each, an “Investment Advisory Agreement,” and collectively with the Fund
Documents, the "Governing Documents"). Investment restrictions for each Client, if any, are generally
established in the Governing Documents of the applicable Client. An investment in each Fund is
subject to the investment objectives, terms and conditions outlined in the Fund Documents of the
relevant Fund. To the extent that there is any conflict between the disclosures contained in this
brochure and any Fund Documents provided to prospective or existing Fund investors, the applicable
Fund Documents will govern. Sofinnova has agreed to: (i) tailor its advisory services to the individual
needs of certain Clients or Fund investors; and (ii) accept investment restrictions imposed by certain
Clients or Fund investors.
D. The Firm does not participate in wrap fee programs.
E. As of December 31, 2023, the Firm had approximately $3.7 billion in net Client assets under
management (including uncalled capital commitments to the Funds), all of which it managed on a
discretionary basis.